WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Results 1-10 of 2,229 for Criteria: Office(s):all Language:FR Stemming: true maximize
préc. 1 2 3 4 5 6 7 8 9 10 suiv.
Page: / 223  Go >
RSS icon map icon

Analysis
Analysis

List Length
No translation
NoCtrTitlePubDateInt.ClassAppl.NoApplicantInventor
1. WOWO/2013/111105 - IMIDAZOPYRROLIDINONE COMPOUNDS01.08.2013
C07D 487/04
PCT/IB2013/050655NOVARTIS AGFURET, Pascal
The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

2. WOWO/2013/097980 - NIFURATEL SULFOXIDE FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS04.07.2013
C07D 413/12
PCT/EP2012/072856POLICHEM S.A.GAGLIARDI, Stefania
The present invention is directed to nifuratel sulfoxide, in particular, it is directed to the use of nifuratel sulfoxide, or a physiologically acceptable salt thereof, or a physiologically acceptable cocrystal thereof, to treat bacterial infections and, in particular, to treat infections caused by Atopobiwn and Gardnerelkt species. The invention is further directed to the use of nifuratel sulfoxide to treat bactenuria, urinary tract infections, infections of external genitalia in both sexes, as well as bacterial vaginosis, or mixed vaginal infections in women, when one or more species of the genera Atopobiwn and GardnereUa are among the causative pathogens of those infections.

3. WOWO/2013/090921 - NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF20.06.2013
C07D 311/00
PCT/US2012/070168OLEMA PHARMACEUTICALS, INC.KUSHNER, Peter, J.
Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP- 1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-l-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin- 1 -yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.

4. WOWO/2013/072415 - BINDING MOLECULES FOR BCMA AND CD323.05.2013
C07K 16/28
PCT/EP2012/072730AMGEN RESEARCH (MUNICH) GMBHKUFER, Peter
The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

5. WOWO/2013/072406 - BINDING MOLECULES FOR BCMA AND CD323.05.2013
C07K 16/28
PCT/EP2012/072699AMGEN RESEARCH (MUNICH) GMBHKUFER, Peter
The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain,wherein the first binding domain is capable of binding to epitope cluster3 of BCMA,and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

6. WOWO/2013/070176 - A METHOD FOR RECYCLING WASTE THERMOPLASTIC MATERIALS AND USING THIS RECYCLED THERMOPLASTIC IN COMPOSITE MATERIAL PRODUCTION16.05.2013
C08J 11/04
PCT/TR2011/000265GUVEN, Ali HakanGUVEN, Ali Hakan
This invention is related to a method for production of high strength and low cost thermoplastic composite materials by processing and treating waste plastic materials with some minerals. The object of the invention is to embody a recycling method wherein it contains high amounts of additives and therefore composite materials with high strength properties are obtained. Another object of the invention is to embody a recycling method wherein high amounts of additives are used in the production and the machines used in the production are not damaged.

7. WOWO/2013/068299 - DEICING COMPOSITION16.05.2013
C09K 3/18
PCT/EP2012/071678AKZO NOBEL CHEMICALS INTERNATIONAL B.V.MASLOW, Wasil
The present invention relates to a deicing composition comprising (i) a deicing agent selected from the group consisting of sodium chloride, calcium magnesium acetate, calcium chloride, magnesium chloride, potassium chloride, potassium acetate, sodium acetate, sodium formate, potassium formate, (ii) a lignin derivative, and (iii) molasses. It furthermore relates to a process for preparing said deicing composition and to a process for deicing a surface using said deicing composition.

8. WOWO/2013/068875 - 2-THIOPYRIMIDINONES16.05.2013
C07D 239/56
PCT/IB2012/055949PFIZER INC.CARPINO, Philip, Albert
Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

9. WOWO/2013/068774 - THERAPEUTIC COMBINATION OF MEMANTINE AND BACLOFEN AND PHARMACEUTICAL COMPOSITION CONTAINING THEM16.05.2013
A61K 31/13
PCT/HU2012/000119RICHTER GEDEON NYRT.KOVÁCS, Péter
The present invention relates to the combination of memantine and baclofen active ingredients, and also to the method for achieving body weight loss and thereby treating obesity and related co-morbidities by co-administration of baclofen and memantine.

10. WOWO/2013/067141 - N- (3- { [ (3- { [2-CHLORO-5- (METHOXY) PHENYL] AMINO} QUINOXALIN- 2 -YL) AMINO] SULFONYL} PHE NYL) - 2 -METHYLALANINAMIDE AS PHOSPHATIDYLINOSITOL 3 - KINASE INHIBITOR FOR THE TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANCIES10.05.2013
A61K 31/498
PCT/US2012/062999EXELIXIS, INC.DECILLIS, Arthur
Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compoud A as described herein.


Results 1-10 of 2,229 for Criteria: Office(s):all Language:FR Stemming: true
préc. 1 2 3 4 5 6 7 8 9 10 suiv.